Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report

被引:0
作者
Birgitte Tholin
Marit Teigen Hauge
Pål Aukrust
Lutz Fehrle
Tor Henrik Tvedt
机构
[1] Molde Hospital,Department of Internal Medicine
[2] Molde Hospital,Department of Microbiology
[3] Oslo University Hospital and University of Oslo,Research Institute of Internal Medicine
[4] Oslo University Hospital,Section of Clinical Immunology and Infectious Diseases
[5] Molde Hospital,Department of Anesthesiology
[6] Haukeland University Hospital,Section of Hematology, Department of Internal Medicine
来源
Journal of Medical Case Reports | / 14卷
关键词
COVID-19; HLH; Hemophagocytic lymphohistiocytosis; IL-6; Tocilizumab; Case report;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 48 条
[1]  
Mehta P(2020)COVID-19: consider cytokine storm syndromes and immunosuppression Lancet 395 1033-1034
[2]  
McAuley DF(2003)High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation J Rheumatol 30 1027-1028
[3]  
Brown M(2011)How I treat hemophagocytic lymphohistiocytosis Blood 118 4041-4052
[4]  
Lambotte O(2016)Performances of the H-score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients Am J Clin Pathol 145 862-870
[5]  
Cacoub P(2012)Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases Clin Rheumatol 31 1223-1230
[6]  
Costedoat N(2010)Histiocytic disorders: recent insights into pathophysiology and practical guidelines Biol Blood Marrow Transplant 16 S82-S89
[7]  
Le Moel G(2020)Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality Int J Antimicrob Agents 55 105954-631
[8]  
Amoura Z(2020)NLRP3 inflammasome—a key player in antiviral responses Front Immunol 11 211-e31
[9]  
Piette JC(2020)Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach J Med Virol 92 618-151
[10]  
Jordan MB(2020)Antihypertensive drugs and risk of COVID-19? Lancet Respir Med 8 e30-543